Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors
31 Marzo 2022 - 2:25PM
Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”),
an Australia-based diversified biopharmaceutical enterprise focused
on the research, development, innovation and commercialization of
therapies and products for treatment of global diseases, announced
that it has appointed Dr. John Chiplin as an independent director
to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin
is an accomplished biotech executive and investor with a proven
track record of building successful biotech companies.
Dr. John Chiplin, PhD is Managing Director of
Newstar Ventures Ltd. and Chairman of the Board of Biotherapy
Services, N4 Pharma plc (LSE: N4P) and Scancell Holdings plc. (LSE:
SCLP). Dr. Chiplin has significant operational, investment and
international experience in the life science and technology
industries. From 2014 to 2016, he served as executive director of
Benitec Biopharma Inc. and helped executed the company’s US IPO.
From 2012 to 2014, he was President and Chief Executive Officer of
Polynoma, a Phase III cancer vaccine company, and from 2006 to 2009
he was Chief Executive Officer of Arana Therapeutics. Prior to
this, Dr. Chiplin was head of the ITI Life Sciences investment fund
in the UK, where he managed significant negotiations regarding
funding with Government Ministers. He had been influential in
various other transactions including Intrexon's acquisition of
Medistem, Cephalon's acquisition of Arana Therapeutics, and
GlaxoSmithKline's acquisition of Domantis. He also serves on
several boards including Kings Arms Yard VCT plc and US private
company Batu Biologics. Dr. Chiplin received his doctorate degree
in Pharmaceutical Science from The University of Nottingham,
U.K.
“We believe Dr. Chiplin’s experience in guiding
multiple biotech companies through all stages of development will
be invaluable to Beroni as we advance our robust pipeline through
clinical development with the goal of delivering innovative
therapeutics for oncology patients,” said Jacky Zhang, Chairman,
and CEO of Beroni Group.
“I am honored to join the Board at a pivotal
time for the Company,” said Dr. Chiplin. “Over the last several
years Beroni has created an attractive pipeline of clinical
programs. The Company is now entering its next phase, as it looks
to accelerate its growth globally and raise the capital required
for its next phase of research. I look forward to bringing my
experience to the team and taking part in its journey to becoming a
leading biopharmaceutical company.”
About Beroni Group LimitedBeroni
Group is an international biopharmaceutical enterprise dedicated to
the innovation and commercialization of drugs and therapies to
combat various global diseases such as cancer and infectious
diseases. Its diversified portfolio is comprised of FDA/CE approved
virus diagnostic kits, an e-commerce platform for the sale of
pharmaceutical products and a development pipeline targeting
oncology and cell therapies. Beroni has operations in Australia,
United States, China and Japan. It is listed on the National Stock
Exchange of Australia and traded on the OTC markets in the USA. To
learn more about Beroni, please visit www.beronigroup.com.
Forward-Looking Statements DisclaimerThis
press release contains forward-looking statements or
forward-looking information, within the meaning of applicable
United States and Australian securities laws with respect to the
Company. By their nature, forward-looking statements are subject to
a variety of factors that could cause actual results to differ
materially from the results suggested by the forward-looking
statements. Accordingly, readers should not place undue reliance on
the forward-looking statements. Generally forward-looking
statements can be identified by the use of terminology such as
“anticipate”, “will”, “expect”, “may”, “continue”, “could”,
“estimate”, “forecast”, “plan”, “intend”, “believe”, “potential”
and similar expressions.
Forward-looking information contained in this press release is
based on Company management’s opinions, estimates and assumptions
in light of its experience and perception of historical trends,
current conditions and expected future developments, as well as
other factors that management currently believes are appropriate
and reasonable in the circumstances. Forward-looking statements
involve significant risks, uncertainties and assumptions, and there
can be no assurance that such statements, or its underlying risks,
uncertainties and assumptions will prove to be accurate. Factors
that could cause actual results or events to differ materially
include, without limitation, risks related to laws, rules and
regulation applicable to the Company as well as the industry in
which it operates (including in respect of taxes and other levies),
economic or market conditions on both a national and global level,
currency fluctuations, risks inherent to other entities at a
similar stage of development and industry in which the Company
currently is, competition from the Company’s competitors,
unsatisfactory development or marketing of the Company and/or its
products or services, regulatory action or litigation (including
product liability claims), and failure to enter into agreements or
arrangements with other parties on fair or reasonable terms.
Forward-looking information is made only as of the date on which it
is provided and, except as may be required by applicable laws, the
Company disclaims any intent or obligation to update such
forward-looking information whether as a result of new information,
future events or otherwise.
For more information, please contact our IR
consultants at:Dragon Gate Investment Partners
LLCTel: +1(646)-801-2803Email: BNIGF@dgipl.com
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Apr 2023 a Apr 2024